A malaria pill from the 1940s has caught the eyes of doctors, analysts, and even Elon Musk as a potential coronavirus treatment

businessinsider ^ | 3-18-2020 | Andrew Dunn

[TChad]

As the coronavirus pandemic rages on, some drugs are showing promise in treating patients with COVID-19, the disease caused by the novel coronavirus. There are no approved treatments or vaccines for COVID-19, but researchers are testing a slew of existing drugs to see if they could work. One of those drugs is called chloroquine, a widely used anti-malaria pill that was first approved in the US in 1949. Countries including China, South Korea, and Belgium have added it to COVID-19 treatment guidelines as anecdotal reports have suggested that it might work.

[TChad]

If this works, it will be good news. Chloroquine is an old, well-understood, inexpensive drug, that can be taken orally. It can have undesirable side effects.

[OKITRUMP77]

The cost is 5 cents per pill. Today on Carlson’s show, a test of 40 victims in Italy and 100 success rate. Let’s hope and pray for this.

[kaehurowing]

Pour me another gin and tonic.

[TChad]

Chloroquine side effects:

https://www.drugs.com/sfx/chloroquine-side-effects.html

[TChad]

Pour me another gin and tonic.

I wish. The dosage is too low.

[Army Air Corps]

I have taken Chloroquine.

[TChad]

Today on Carlson’s show, a test of 40 victims in Italy and 100 success rate.

Thank you! That's exactly the sort of info I was looking for, and exactly the result I was hoping for.

[rightwingcrazy]

I think guzzling about 6 quarts of tonic water a day would give an adequate dose.

[TChad]

I have taken Chloroquine.

Did you have bad diarrhea? Any other side effects?

[US Navy Vet]

So have I, NASTY NASTY NASTY!!!

[TianaHighrider]

Reads like every other book of side effects that comes with nearly all drugs these days.

[crz]

“chloroquine “MAY” cause some unwanted effects”

[SeekAndFind]

SEE ALSO HERE:

French researcher posts successful Covid-19 drug trial that stops virus on 24 patients; US scientific researchers, replicate test with similar results

AND HERE:

An effective treatment for #Coronavirus #COVID-19 has been found in a common anti-malarial drug

[Army Air Corps]

Luckily, I suffered no ill effects.

[SeekAndFind]

I heard about this study from radio talk show host, Kevin McCullough

Here is his tweet with video of what he discovered as he interviewed researchers:

https://twitter.com/KMCRadio?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor

For the scientifically inclined with the patience to read through the research study, here is the paper written about the results at Johns Hopkins University that replicated the French study:

https://docs.google.com/document/d/e/2PACX-1vTi-g18ftNZUMRAj2SwRPodtscFio7bJ7GdNgbJAGbdfF67WuRJB3ZsidgpidB2eocFHAVjIL-7deJ7/pub

TITLE:

An Effective Treatment for Coronavirus (COVID-19)

Presented by: James M. Todaro, MD (Columbia MD, jtodaro2@gmail.com) and Gregory J. Rigano, Esq. (grigano1@jhu.edu)

In consultation with Stanford University School of Medicine, UAB School of Medicine and National Academy of Sciences researchers.

March 13, 2020

[Truthoverpower]

Risky lots of side effects. Cheap. Simple.

Silver ions. Much Better. More effective. No cost. No downside

[US Navy Vet]

My First Ship(USS Independence CV-62) pulled into Pt Louis Mauritius in 1981 and the WHOLE Ship had to take this HELLHOLE Drug before we made port and(I think) when we left we had to take ANOTHER HELLHOLE Drug(I forget the name. 3 weeks of HELL just for one SHITTY Port.

[TChad]

So have I, NASTY NASTY NASTY!!!

Please share the gruesome details.

[Zeppelin]

Pour me another gin and tonic.

I wish. The dosage is too low.

Then pour me another!

[SeekAndFind]

Please cite this work as Gautret et al. (2020) Hydroxychloroquine and azithromycin as a treatment of COVID‐19: results of an open‐label non‐randomized clinical trial. International Journal of Antimicrobial Agents – In Press 17 March 2020 – DOI : 10.1016/j.ijantimicag.2020.105949

CLICK THIS LINK for the PDF document of this study

---

MORE FROM THIS ARTICLE:

(EXCERPT)

While unpublished yet, the first patient trial of Plaquenil for COVID-19, conducted in Marseilles, France, has reported encouraging early results. The trial, announced in a video on Monday, was led by Didier Raoult, a physician-scientist who has published on microbes for several decades.

According to a draft article by Raoult’s team and obtained by me, 36 patients were enrolled in the trial, including 16 infected controls and 20 treated patients. The test group was given 600 mg daily of Plaquenil, which is on the WHO’s List of Essential Medicines and has been used for malaria, rheumatoid arthritis and lupus.

At day three, the study reported, 50 percent of the treated group turned from positive to negative for the COVID-19 virus. By day six, 70 percent tested negative.

As intriguing, of the 20 test patients, six who were treated with both Plaquenil and the antibiotic azithromycin did even better, the team reported. Five of the six, or 83 percent, tested negative at day three. All six, 100 percent, tested negative at day six.

Meanwhile, the control patients largely stayed sick longer. On days three and six, just 6.3 percent and 12.5 percent, respectively, tested negative. The research paper did not include how they were alternatively treated.

Raoult’s findings prompted the French Minister of Health Tuesday to approve expanded treatment trials, with one commencing in Lille, according to France 3, a public television station.

Please cite this work as Gautret et al. (2020) Hydroxychloroquine and azithromycin as a treatment of COVID‐19: results of an open‐label non‐randomized clinical trial. International Journal of Antimicrobial Agents – In Press 17 March 2020 – DOI : 10.1016/j.ijantimicag.2020.105949

CLICK THIS LINK for the PDF document of this study

---

MORE FROM THIS ARTICLE:

(EXCERPT)

While unpublished yet, the first patient trial of Plaquenil for COVID-19, conducted in Marseilles, France, has reported encouraging early results. The trial, announced in a video on Monday, was led by Didier Raoult, a physician-scientist who has published on microbes for several decades.

According to a draft article by Raoult’s team and obtained by me, 36 patients were enrolled in the trial, including 16 infected controls and 20 treated patients. The test group was given 600 mg daily of Plaquenil, which is on the WHO’s List of Essential Medicines and has been used for malaria, rheumatoid arthritis and lupus.

At day three, the study reported, 50 percent of the treated group turned from positive to negative for the COVID-19 virus. By day six, 70 percent tested negative.

As intriguing, of the 20 test patients, six who were treated with both Plaquenil and the antibiotic azithromycin did even better, the team reported. Five of the six, or 83 percent, tested negative at day three. All six, 100 percent, tested negative at day six.

Meanwhile, the control patients largely stayed sick longer. On days three and six, just 6.3 percent and 12.5 percent, respectively, tested negative. The research paper did not include how they were alternatively treated.

Raoult’s findings prompted the French Minister of Health Tuesday to approve expanded treatment trials, with one commencing in Lille, according to France 3, a public television station.

MORE FROM THIS ARTICLE:

(EXCERPT)

While unpublished yet, the first patient trial of Plaquenil for COVID-19, conducted in Marseilles, France, has reported encouraging early results. The trial, announced in a video on Monday, was led by Didier Raoult, a physician-scientist who has published on microbes for several decades.

According to a draft article by Raoult’s team and obtained by me, 36 patients were enrolled in the trial, including 16 infected controls and 20 treated patients. The test group was given 600 mg daily of Plaquenil, which is on the WHO’s List of Essential Medicines and has been used for malaria, rheumatoid arthritis and lupus.

At day three, the study reported, 50 percent of the treated group turned from positive to negative for the COVID-19 virus. By day six, 70 percent tested negative.

As intriguing, of the 20 test patients, six who were treated with both Plaquenil and the antibiotic azithromycin did even better, the team reported. Five of the six, or 83 percent, tested negative at day three. All six, 100 percent, tested negative at day six.

Meanwhile, the control patients largely stayed sick longer. On days three and six, just 6.3 percent and 12.5 percent, respectively, tested negative. The research paper did not include how they were alternatively treated.

Raoult’s findings prompted the French Minister of Health Tuesday to approve expanded treatment trials, with one commencing in Lille, according to France 3, a public television station.